BTG TO BEGIN CLINICAL SAFETY STUDY OF VARISOLVE

BTG intends to complete preparations for and commence a Phase II clinical safety study of Varisolve, the novel injectable microfoam treatment for varicose veins.

The Phase II study will explore the safety of Varisolve in 50 patients who have a patent foramen ovale (PFO), a defect whereby the small hole that connects the right and left atria of the heart to improve foetal circulation does not close at birth. PFOs are estimated to be present in approximately 20 percent of the population. Under certain conditions, they allow blood (and potentially clots, particles or bubbles within the blood) to travel from the right atrium into the left atrium, then out of the heart and into the arterial system.